I
N THE PREANTIBIOTIC ERA, NATIVE valve endocarditis was virtually always fatal. Since the advent of antibiotic therapy, mortality decreased to 24% to 60% in published case series, with heart failure representing the leading cause of death. [1] [2] [3] [4] During the past 3 decades, studies have suggested that valve surgery should be considered for patients with native valve endocarditis associated with complications that adversely affect prognosis: heart failure, [5] [6] [7] [8] [9] [10] new valvular regurgitation, [11] [12] [13] refractory infection (ie, persistent fever or bacteremia, fungemia, or paravalvular abscess), 14, 15 systemic embolization to vital organs, 16, 17 and the presence of a vegetation on echocardiography as this represents a plausible risk for embolization. [18] [19] [20] However, methodological limitations of existing studies, the absence of randomized controlled trials, and the lack of a validated method to classify prognostic severity make management decisions problematic.
Accurate prognostic classification may help facilitate individual treatment decisions and interpretation of therapeutic interventions in clinical trials. In this study, we derived and externally validated a prognostic classification system in 2 contemporaneous cohorts of adults with complicated leftsided native valve endocarditis.
METHODS

Patients
Research patients were identified through systematic medical record review at the 7 Connecticut hospitals where valve surgery was performed. To create and test a prognostic classification system, we divided patients into derivation and validation cohorts (FIGURE) . The derivation cohort (n = 259) was assembled from adults (Ͼ16 years) in whom complicated leftsided native valve endocarditis was di-agnosed at 1 of 5 hospitals serving New Haven (Yale-New Haven Hospital, Hospital of St Raphael), West Haven (Veterans Administration Connecticut Health Care System), and Bridgeport (Bridgeport Hospital and St Vincent's Hospital), Conn, from January 1990 to January 2000.
The validation cohort (n = 254) was assembled similarly during the same period for patients given a diagnosis at 2 hospitals serving a separate geographic location in Hartford, Conn (Hartford Hospital and St Francis Hospital). Patients were identified as having infective endocarditis if they met the Duke criteria for definite or possible endocarditis. 21 Patients were included if they had leftsided involvement of a native valve (aortic valve, mitral valve, or both) and they had exhibited a clinical complication for which valve surgery is considered in current clinical practice: congestive heart failure, new valvular regurgitation, refractory infection, systemic embolization to vital organs, or presence of a vegetation on echocardiography. For patients with multiple episodes of endocarditis, only the first episode was analyzed. Patients were excluded if they were comatose at baseline, if clinical outcome data were not available 6 months after baseline, or if the decision about surgery was not explicitly stated in the medical record. The study was approved by the Human Investigation Committee at Yale University School of Medicine as well as by the institutional review boards of all 7 participating hospitals.
Clinical Data
From medical records, baseline clinical information was systematically extracted on sociodemographic data, comorbid conditions, previous heart disease, exposures, symptoms, physical findings, blood cultures, electrocardiogram, echocardiography, as well as the type and duration of therapy (TABLE 1) . Baseline features were assessed at a specified baseline defined as the date of valve surgery or the date that the decision not to operate was recorded in the medical record. Comorbidity was assessed by using the Charlson comorbidity scale, 22 which assigns weights to specific comorbid disease states: 1 point (myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disease, ulcer disease, mild liver disease, diabetes), 2 points (hemiplegia, moderate to severe renal disease, diabetes with endorgan damage, any tumor, leukemia, lymphoma), 3 points (moderate to severe liver disease), and 6 points (metastatic solid tumor or acquired immunodeficiency syndrome).
Outcomes
The primary outcome was all-cause mortality at 6 months after baseline. All patient episodes were followed up for the 6-month period after baseline for survival or death. For patients whose medical records lacked documentation of survival or death 6 months after baseline, the National Death Index was used to determine outcome. The National Death Index has demonstrated accuracy of 97% to 100% in determining vital status, and may have superiority over other databases in determining date of death.
23-25
Statistical Analyses
After a comprehensive descriptive comparison of derivation and validation cohorts, bivariate analyses were performed to detect associations of clinically plausible baseline features with 6-month mortality. Cutoff levels of continuous variables were chosen to be clinically meaningful. Differences in proportions were tested by using the 2 test or the Fisher exact test. For contrasts of continuous variables, the t test and the Wilcoxon rank sum test were used. Baseline features of the derivation cohort associated with death in bivariate analyses were subject to multivariable analyses using stepwise logistic regression modeling to identify predictors based on the likelihood ratio test. Clinically plausible interactions among baseline variables were also tested. The adjusted odds ratio (OR) from the logistic regression was converted to relative risk (RR) using the formula:
where P is the incidence of the outcome event in the nonexposed group. 26 No more than 1 variable per 10 outcome events was entered in logistic models to avoid overfitting. 27 The goodness-of-fit of the final model was examined by using the HosmerLemeshow test. Using the independently prognostic baseline variables identified in logistic modeling, we developed a weighted scoring assignment using linear transformation of parameter coefficients that classified patients into 4 quartiles of risk for death 6 months after baseline.
Model calibration was assessed by comparing predicted and observed mortality rates in the validation cohort. Model discrimination was measured by using the concordance index. 28 This statistic describes the likelihood that among any 2 randomly chosen patients where 1 died and 1 did not the model would have correctly chosen which one was at more risk. All analyses were conducted by using SAS version 8.02 (SAS Institute, Cary, NC). PϽ.05 was considered statistically significant. Any rales 140 (27) 78 (30) 62 (24) .12
Other (wheezing, rhonchi, or pleural friction rub) 28 (5) 15 (6) 13 (5) New York Heart Association class IV heart failure 105 (20) 56 (22) 49 (19) .51
Abnormal skin findings (splinter hemorrhage, Janeway lesions, Osler nodes or petechiae)
142 (28) 63 (24) 79 (31) .09
Visual loss 27 (5) 12 (5) 15 (6) .52
Monoarticular and oligoarticular arthritis 71 (14) 35 (14) 36 (14) .83
Splenomegaly 60 (12) 35 (14) 25 (10 (28) 75 (30) 68 (27) Enterococcus 58 (11) 30 (12) 28 (11) .81
Other streptococci 57 (11) 26 (10) 31 (12) Coagulase-negative Staphylococcus 38 (7) 23 (9) 15 (6) Other 21 (4) 15 (6) 6 (2) SI conversion factor: To convert serum creatinine to µmol/L, multiply by 88.4.
*Data represented at baseline, defined as the date of surgery or the date the decision was made not to operate. P values are comparison of derivation vs validation cohorts. †Scale assigned weights as specified in "Methods." ‡Patients with human immunodeficiency virus, acquired immunodeficiency syndrome, solid organ or bone marrow transplantation, receiving steroids (Ն20 mg of prednisone or equivalent for Ͼ1 month), end-stage renal disease, or recent chemotherapy (Ͻ1 month). §Includes rheumatic valve disease, nonrheumatic valve disease, previous endocarditis, congenital heart disease, degenerative cardiac disease, and ischemic cardiomyopathy. Cardiac murmur heard on auscultation during current episode of endocarditis in the absence of either a history of heart murmur or a valvular abnormality on a previous echocardiogram. ¶Numbers do not sum because some patients had more than 1 type of microorganism isolated. Other organisms included Enterobacteriaceae, other gram-negative rods, HACEK (Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella) group of organisms, and fungi.
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RESULTS
Cohort Identification
After initial screening of 1611 medical records at the 7 hospitals, 513 patient episodes met eligibility criteria for inclusion in the study as having complicated left-sided native valve endocarditis: 259 patients in the derivation cohort and 254 patients in the validation cohort (Figure) .
Baseline Features, Microbial Etiologies, and Clinical Outcome
Baseline patient features and microbial etiologies are shown in Table 1 ; imaging studies, clinical complications, surgical findings, and clinical outcome are shown in TABLE 2. The derivation and validation cohorts were similar with respect to age, sex, race, presence of comorbid disease, immunocompetence, and underlying cardiac disease. Baseline clinical features were also similar, but significantly more patients in the validation cohort had a heart murmur, echocardiographic evidence of an intracardiac abscess, combined aortic and mitral valve involvement, operative documentation of a valvular vegetation and myocardial abscess, and surgery performed primarily related to a greater proportion of bioprosthetic valve replacements. For the total cohort, fever (78%, n = 400) and dyspnea (33%, n = 169) were the most common presenting symptoms; mitral valve involvement was observed in 257 patients (50%), aortic valve involvement in 180 patients (35%), and both mitral and aortic valves were involved in 76 patients (15%). Clinical complications raising the issue of surgery for the total cohort included anatomic abnormalities in 511 patients (echocardiographic evidence of vegetation in 443 patients [86%]; new valve regurgitation in 335 patients [65%]), moderate or severe congestive heart failure in 222 patients (44%), symptomatic embolic disease in 116 patients (23%), and refractory infection in 109 patients (21%). Overall, 499 patients (97%) of the total cohort met Duke criteria for definite endocarditis with the most common bacterial etiologies being viridans streptococci (36%, n=183), Staphylococcus aureus (28%, n=143), Enterococcus (11%, n = 58), and other streptococci (11%, n=57). Valve surgery was performed on 230 patients (45%) in the total cohort: 109 (21%) had mechanical valve replacement, 102 (20%) had bioprosthetic valve replacement, and 20 (4%) had valve repair (1 patient in the validation cohort had Ͼ1 procedure performed). The mortality rate for the total cohort was 26% (n=131) and was similar in the derivation and validation cohorts (25% and 26%, respectively).
Associations of Baseline Features With 6-Month Mortality
Bivariate analyses relating baseline features to 6-month mortality in the derivation cohort are shown in TABLE 3. Comorbidity (Charlson score Ն2), an immunocompromised state, fever by physical examination, abnormal mental status, and moderate to severe congestive heart failure were clinical features that all showed bivariate association with 6-month mortality. Similarly, bacterial etiologies other than viridans streptococci (particularly S aureus and Enterococcus) were associated with 6-month mortality as well as medical therapy without valve surgery.
Development and Validation of Prognostic Classification System
To determine independent associations with 6-month mortality, all biologically plausible variables showing bivariate associations were entered into a logistic regression model (TABLE 4) . In this model, abnormal mental status, comorbidity, moderate to severe congestive heart failure, S aureus, and other nonviridans streptococci bacterial etiologies remained independently associated with 6-month mortality. Medical therapy without valve surgery also remained significantly associated with 6-month mortality. Using the 5 independently predictive features from the logistic regression model, we developed a prognostic classification system. As an initial step, the 5 predictive baseline features were assigned point scores based on a linear transformation of the parameter coefficients rounded to the closest integer. The resulting scoring system of the 5 predictive features is shown in Table 4 . Using this scoring system, prognostic classification was developed in which patients were assigned to 4 prognostic groups based on quartiles of risk for 6-month mortality as follows: group 1 (Յ6 points), group 2 (7-11 points), group 3 (12-15 points), and group 4 (Ͼ15 points). As shown for the derivation cohort in TABLE 5, the observed number of patients who died in the 6-month follow-up period were 3 (5%) in group 1, 10 (15%) in group 2, 22 (31%) in group 3, and 31 (59%) in group 4 (PϽ.001).
For the validation cohort, the observed number of patients who died in the 6-month follow-up period were 6 (7%) in group 1, 15 (19%) in group 2, 17 (32%) in group 3, and 27 (69%) in group 4 (PϽ.001). The HosmerLemeshow goodness-of-fit test yielded P = .32 for the derivation cohort and P=.39 for the validation cohort, demonstrating that no strong evidence supports lack of fit of the model. Calculation of model discrimination by using the concordance index was 0.80 (95% confidence interval [CI], 0.73-0.87) for the derivation cohort; the concordance index for the validation cohort was 0.81 (95% CI, 0.74-0.88).
COMMENT
This study analyzed the largest cohort to date of adults with complicated leftsided native valve endocarditis. Five baseline features predicted 6-month mortality and stratified patients into distinct prognostic groups. The prognostic group classification in the derivation cohort worked well in the validation cohort in terms of both calibration and discrimination.
The decision to perform valve surgery in adults with complicated leftsided native valve endocarditis has been controversial since the advent of valve replacement. 5 Published recommendations have been based on uncontrolled observational data and expert opinions of experienced clinicians; no Abbreviations: TEE, transesophageal echocardiography; TTE, transthoracic echocardiography.
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*Data (except 6-month mortality) represented at baseline, defined as the date of surgery or the date the decision was made not to operate. P values are comparison of derivation vs validation cohorts. Numbers do not sum for anatomic abnormalities, surgery performed, and operative findings, because either several patients had more than 1 abnormality or 1 patient in the validation cohort had more than 1 procedure performed. †Represents echocardiographic finding with TEE if patient underwent both TEE and TTE or TEE alone; otherwise, represents finding with TTE. ‡Regurgitation demonstrated on echocardiography during current episode of endocarditis with no evidence of regurgitation on a previous echocardiogram. In the absence of a previous echocardiogram, regurgitation was observed for the first time during the current episode. §Regurgitation that was documented on a previous echocardiogram and was unchanged on the current echocardiogram. Changes in echocardiogram appearance suggesting embolization, old valve regurgitation with or without myocardial dysfunction. ¶None or mild: absence of rales on examination, no shortness of breath at rest, and no pulmonary edema on chest radiograph; moderate: presence of only 1 or 2; and severe: presence of all 3. #Patients with symptoms as a direct consequence of embolic phenomenon that were not disabling (include cerebrovascular, joint, major artery, eye, spleen, liver, kidney, and skin emboli).
**Cerebrovascular accident, blindness, or major arterial emboli (emboli to extremities requiring amputation, mesenteric arterial emboli leading to intestinal infarction, or coronary emboli resulting in myocardial infarction). † †Includes cerebrovascular, joint, major artery, eye, spleen, liver, kidney, and skin.
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(Reprinted) JAMA, April 16, 2003 -Vol 289, No. 15 1937 prospective randomized trials have been performed. As a result, clinical decisions are often based on anecdotal prognostic estimates of individual patients by practicing physicians without validated evidence. In this study, a rigorously identified cohort of adults with complicated native valve endocarditis was analyzed to derive and validate a prognostic classification system for adults with complicated left-sided native valve endocarditis. This system may assist management decisions for individual patients.
Baseline clinical features and microbial etiologies of our cohort were similar to previous cohorts of adults with leftsided native valve endocarditis. The mortality rate of 26% for the total cohort is higher than in most case series but likely reflected the strict inclusion only of patients with complicated disease at baseline. 1 For developing a prognostic classification system, all-cause 6-month mortality was used as the end point to reflect a clinically logical outcome and to minimize detection bias by using the National Death Index to supplement medical record information.
Our study design provided several advantages and avoided the methodological limitations of previous observational cohorts. First, our study cohort was large, yet restricted to adults with left-sided native valve endocarditis who manifested complications at baseline for which valve surgery is considered in contemporary clinical practice (ie, congestive heart failure, new valvular regurgitation, systemic embolization to major organs, refractory infection, or the presence of an echocardiographically identifiable vegetation). Second, our study specified a baseline at which clinical features were assessed for each patient. 29 The definitions used resulted in the same median duration of time from admission to baseline for patients who underwent surgery and those who did not (6 days; comparing medically and surgically treated patients, P=.97), and they fostered reproducibility of the prognostic classification system between the derivation and validation cohorts. Iden- Abbreviations: TEE, transesophageal echocardiography; TTE, transthoracic echocardiography.
*None or mild: absence of rales on examination, no shortness of breath at rest, and no pulmonary edema on chest radiograph; moderate to severe: presence of at least 1. †Aortic valve refers to patients with either isolated aortic valve involvement or aortic valve involvement in combination with other valve involvement. ‡Refers to cerebrovascular accident, blindness, or major arterial emboli. §Other includes Staphylococcus aureus, other streptococci, Enterococcus, coagulase-negative Staphylococcus, Enterobacteriaceae, other gram-negative rods, HACEK group of organisms (see Table 1 footnote), fungi, and culturenegative endocarditis. Other includes viridans Streptococcus, other streptococci, Enterococcus, coagulase-negative Staphylococcus, Enterobacteriaceae, other gram-negative rods, HACEK group of organisms, fungi, and culture-negative endocarditis. ¶Other includes viridans streptococci, S aureus, other streptococci, coagulase-negative Staphylococcus, Enterobacteriaceae, other gram-negative rods, HACEK group of organisms, fungi, and culture-negative endocarditis.
tification of a specific baseline fosters generalizability of prognostic assessment among different cohorts of patients; it is particularly important for patients with endocarditis as clinical findings can evolve rapidly. Third, our study used a validated comorbidity index to analyze the impact of comorbidity on risk of death. This index incorporates both the number and severity of underlying disease and was demonstrated to independently predict 6-month mortality in our cohort. Fourth, our prognostic model and classification system were created by using baseline variables that were explicitly defined, clinically plausible, and identifiable by the physician at the bedside, which also fostered reproducibility and practical use. Finally, we tested the model and prognostic classification system in a distinct validation cohort during the same 10-year period. The 5 baseline features (comorbidity, moderate-to-severe congestive heart failure, altered mental status, bacterial etiology other than viridans streptococci, and medical therapy without valve surgery) that were independently associated with 6-month mortality represent plausible predictors from clinical experience and published literature. Comorbidity, as measured by the Charlson comorbidity scale, has already been validated as predictor of short-term and long-term mortality in adult patients. 22 Higher rates of microbiological relapse and mortality have been traditionally recognized for S aureus, Enterococcus, and other species when compared with viridans streptococci. 1 Congestive heart failure (primarily related to severe valve dysfunction) has been repeatedly reported as the most common cause of death in native valve endocarditis, [6] [7] [8] [9] [10] and altered mental status (defined as lethargy or disorientation) has biological plausibility as it represents a marker of overall disease severity (eg, poor cerebral perfusion, metabolic instability, and inflammatory cytokine release) of the microbial sepsis syndrome. Medical therapy without valve surgery has been associated with poor outcome for patients with complicated endocarditis, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] particularly in observational studies of patients with congestive heart failure and S aureus bacterial etiology. 9, 30, 31 Although our study had several methodological advantages, there were limitations. Our cohort of patients was assembled retrospectively, making detection bias in determination of baseline features and clinical outcome an unavoidable possibility. However, our established baseline, rigorous definitions of baseline clinical features, and use of 6-month mortality as the clinical end point all decreased this potential bias. The reproducibility of the classification system in both derivation and validation cohorts supports the contention that this bias was minimized. Our strategy of using mortality as the end point limited the value of the classification system. Prognostic classification of morbidity outcomes (eg, stroke, persistent congestive heart failure, hospitalization, and overall quality of life) are *The parameter coefficient and Wald P value were estimated using logistic regression. Relative risk and confidence interval are estimated using the formula stated in the "Methods." Discrete score was modified by linear transformation of the parameter coefficient taken from logistic regression (divided by 0.25) and then rounded to the closest integer. †None or mild: absence of rales on examination, no shortness of breath at rest, and no pulmonary edema on chest radiograph; moderate to severe: presence of at least 1. ‡Includes other streptococci, Enterococcus, coagulase-negative Staphylococcus, Enterobacteriaceae, other gramnegative rods, HACEK group of organisms (see Table 1 footnote), fungi, and culture-negative endocarditis. * equally valuable and could not be performed using our study design. Although valve surgery was associated with a decreased risk of 6-month mortality in the multivariable model adjusting for other prognostic variables, this was a nonrandomized treatment assignment. Therefore, other potential confounding and treatment selection biases may have existed that limit conclusions about the benefit of surgery. The fact that patients treated at hospital sites in the validation cohort underwent valve surgery more frequently than patients in the derivation cohort supports the possibility of regional treatment selection biases. Further investigations using methods (eg, propensity analyses) that account for these potential confounding and treatment selection biases will be required to render a more rigorous adjustment than would be possible with standard multivariable techniques. 32, 33 Our current study cannot be used as evidence that switching from a medical to surgical strategy will necessarily improve survival. Finally, given that the decision to treat medically or surgically may vary between physicians, the actual predictive value of our system may vary according to when or how that decision is made and the system has unknown ability when applied at different points in a patient's course; further study is needed.
Physicians must recognize that our results apply to a restricted group of patients with complicated left-sided native valve endocarditis and not to all patients with endocarditis. Nonetheless, the observations in this study will provide immediate and future guidance for the practicing clinician. Accurate prognostic classification of risk for 6-month mortality among patients with complicated left-sided native valve endocarditis can be performed using available clinical data at the bedside. This may facilitate more reliable discussions among patients and their physicians as to the intensity, type, and expectations of treatment. They provide quantitative stratification of mortality risk for future observational assessments and potential randomized clinical trials of valve surgery for adults with leftsided native valve endocarditis. Future studies of prospective cohorts are needed to stratify risk for important morbidity outcomes.
